丽珠医药(01513)拟对越南IMP发起公开要约收购 获当地监管正式批复

公告速递
Mar 06

丽珠医药(01513)发布公告,旗下境外全资子公司LIAN SGP HOLDING PTE.LTD.(「LIAN SGP」)已完成向越南国家证券委员会提交对Imexpharm Corporation(「IMP」)股份的公开要约收购申请,并正式获得同意批复。

丽珠医药在2025年5月22日及2025年12月30日召开董事会,审议通过收购及公开要约收购IMP股权相关议案。根据公告,LIAN SGP将依据越南相关规定,向IMP全体股东发出收购要约。

公司方面强调,本次交易后续进展仍受市场变化及相关审批程序等因素影响,存在不确定性。丽珠医药表示,将依据中国及香港等地相关法律和规则,及时履行所需的审批及信息披露义务。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10